Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-10.97%
operating margin TTM
-17.15%
revenue TTM
510.38 Million
revenue per share TTM
4.8$
valuation ratios | |
|---|---|
| pe ratio | -181.26 |
| peg ratio | -11.26 |
| price to book ratio | 11.79 |
| price to sales ratio | 20.50 |
| enterprise value multiple | -122.44 |
| price fair value | 11.79 |
profitability ratios | |
|---|---|
| gross profit margin | 91.63% |
| operating profit margin | -17.15% |
| pretax profit margin | -10.9% |
| net profit margin | -10.97% |
| return on assets | -5.46% |
| return on equity | -7.4% |
| return on capital employed | -10.05% |
liquidity ratio | |
|---|---|
| current ratio | 6.36 |
| quick ratio | 6.23 |
| cash ratio | 1.49 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 168.41 |
| operating cycle | 257.70 |
| days of payables outstanding | 167.07 |
| cash conversion cycle | 90.63 |
| receivables turnover | 4.09 |
| payables turnover | 2.18 |
| inventory turnover | 2.17 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.01 |
| debt equity ratio | 0.01 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.01 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -4.31 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.71 |
| cash per share | 9.71 |
| operating cash flow per share | -0.71 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -4.31 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -227.26 |
Frequently Asked Questions
When was the last time Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) reported earnings?
Intra-Cellular Therapies, Inc. (ITCI) published its most recent earnings results on 30-10-2024.
What is Intra-Cellular Therapies, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)'s trailing twelve months ROE is -7.4%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Intra-Cellular Therapies, Inc. (ITCI) currently has a ROA of -5.46%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did ITCI's net profit margin stand at?
ITCI reported a profit margin of -10.97% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is ITCI's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 6.36 in the most recent quarter. The quick ratio stood at 6.23, with a Debt/Eq ratio of 0.01.